![Steven J. Swanson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Steven J.
Swanson worked as the Head of Clinical Immunology at Amgen, Inc. He then worked as the Senior Vice President of Research at ImmunoCellular Therapeutics Ltd.
from 2015 to 2018.
Swanson received his undergraduate degree from North Central College and his doctorate from the University of Iowa.
Eerdere bekende functies van Steven J. Swanson
Bedrijven | Functie | Einde |
---|---|---|
EOM PHARMACEUTICALS HOLDINGS, INC. | Hoofd Techniek/Wetenschap/O&O | 15-10-2018 |
AMGEN INC. | Corporate Officer/Principal | - |
Opleiding van Steven J. Swanson
North Central College | Undergraduate Degree |
University of Iowa | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AMGEN INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
ImmunoCellular Therapeutics Ltd.
![]() ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |